

38. Wang Y, Rathinam R, Walch A, Alahari SK: ST14 (suppression of tumorigenicity 14) gene is a target for miR-27b, and the inhibitory effect of ST14 on cell growth is independent of miR-27b regulation. *J Biol Chem* 2009, **284**:23094-23106.
39. Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D, So CW: beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. *Cancer Cell* **18**:606-618.
40. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZ: Evidence of a Role for Activation of Wnt/ β -Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide. *J Biol Chem* **286**:11009-11020.
41. Senthivanayagam S, Mishra P, Paramasivam SK, Yallapragada S, Chatterjee M, Wong L, Rana A, Rana B: Caspase-mediated cleavage of beta-catenin precedes drug-induced apoptosis in resistant cancer cells. *J Biol Chem* 2009, **284**:13577-13588.
42. Zhang X, Wang T, Batist G, Tsao MS: Transforming growth factor beta 1 promotes spontaneous transformation of cultured rat liver epithelial cells. *Cancer Res* 1994, **54**:6122-6128.
43. Caja L, Sancho P, Bertran E, Iglesias-Serret D, Gil J, Fabregat I: Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF- β -induced cell death through impairing up-regulation of the NADPH oxidase NOX4. *Cancer Res* 2009, **69**:7595-7602.

doi:10.1186/1476-4598-10-135

Cite this article as: Yamamoto *et al.*: An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. *Molecular Cancer* 2011 **10**:135.

Submit your next manuscript to BioMed Central
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



A Thick Pancreas Is a Risk Factor for Pancreatic Fistula after a Distal Pancreatectomy: Selection of the Closure Technique according to the Thickness

Hidetoshi Eguchi^a Hiroaki Nagano^a Masahiro Tanemura^a Yutaka Takeda^a
Shigeru Marubashi^a Shogo Kobayashi^a Hiroshi Wada^a Koji Umeshita^b
Masaki Mori^a Yuichiro Doki^a

^aDepartment of Surgery and ^bDivision of Health Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan

Key Words

Distal pancreatectomy · Pancreatic fistula · Stapler

Abstract

Background/Aims: Hand-sewn closures or stapler closures of the pancreatic remnant after a distal pancreatectomy have commonly been employed; however, the choice of technique in each patient depending on their clinical characteristics has not been discussed. **Methods:** Forty-eight patients who underwent a distal pancreatectomy at Osaka University Hospital between January 2007 and October 2009 were enrolled. A hand-sewn closure was planned during the 1st period (before June 2008, 26 consecutive patients), whereas a stapler closure was planned for the 2nd period (after June 2008, 22 consecutive patients). The incidence of pancreatic fistula and the patients' characteristics were retrospectively investigated. **Results:** Seven patients (27%) developed a fistula in the hand-sewn group, while 5 (23%) developed a fistula in the stapler group ($p = n.s.$). Using logistic regression analysis for all patients, younger age and the thickness of the pancreatic remnant were identified as independent risk factors for pancreatic fistula. In the stapler group, 50% of patients with a thick pancreas developed a pancreatic fistula, while no patients with a thin pancreas de-

veloped one. **Conclusion:** Thick pancreas is one of the risk factors for pancreatic fistula after a distal pancreatectomy; however, a stapler closure seems to be suitable at least for thin pancreas.

Copyright © 2011 S. Karger AG, Basel

Introduction

The incidence of pancreatic fistula after a distal pancreatectomy remains high, ranging from 12 to 34%, in spite of the recent progress in both surgical techniques and postoperative management [1–8]. Surgeons have struggled to avoid this troublesome event because a pancreatic fistula is the main trigger for a variety of postoperative complications, such as intra-abdominal hemorrhage, sepsis and ileus. The risk factors for developing a pancreatic fistula has been investigated and previous studies have identified that the method of pancreatic remnant closure, malignancy, trauma, patient age, concomitant splenectomy, obesity, use of prophylactic octreotide therapy, longer operating time, location of pancreatic transection and the texture of the pancreas were all risk factors for pancreatic fistula [2–5, 9]. Several techniques have been advocated to close the pancreatic

remnant in order to reduce the incidence of pancreatic fistula, such as a hand-sewn closure, stapler closure, ultrasonic dissection, seromuscular patches or pancreaticoenteric anastomosis [1, 10–12]. A hand-sewn or stapler closure is the most commonly employed of these methods, and several studies have tried to clarify the superiority of these 2 methods. Some studies have reported the superiority of a stapler closure, whereas other studies find it to be inferior to the hand-sewn technique. A meta-analysis indicated a nonsignificant combined odds ratio for the occurrence of a pancreatic fistula of 0.66 in favor of stapler closure [13]. More recently, a retrospective study based on more than 300 distal pancreatectomies indicated that closure using a stapling device was an independent risk factor for a higher incidence of pancreatic fistula [2].

One possible way to identify a better closure technique is to conduct a randomized clinical trial comparing the incidence of pancreatic fistula after hand-sewn versus stapler closure, and such a trial is now ongoing [14]. A randomized clinical trial can elucidate the superiority of one method over another; however, the overall incidence of pancreatic fistula is unlikely to decrease dramatically because the reported incidence of using either method is similarly high. Given the variability in the pancreatic gland size and texture, choosing the suitable technique of closure depending on the patient's individual characteristics seems to be the best way to reduce the incidence of pancreatic fistula. A hard pancreas is less likely to induce a pancreatic fistula [3, 6, 7]. However, no study has determined whether a hard pancreas is less likely to induce a pancreatic fistula even when compressed by a stapler. Also, we may speculate that a thick pancreas is more likely to be crushed when compressed by a stapler; however, no study has previously investigated the clinical significance of the thickness of the pancreas. Therefore, in the present study, we retrospectively investigated the risk factors for pancreatic fistula using univariate and multivariate analyses, and then separately calculated risk factors in patients who underwent hand-sewn closure or stapler closure in order to clarify the relationship between the thickness and the closure technique.

Patients and Methods

Patients

Forty-eight patients who underwent a distal pancreatectomy at Osaka University Hospital between January 2007 and October 2009 were retrospectively investigated in the present study. A hand-sewn closure of the pancreatic remnant was planned in 26

consecutive patients during the 1st period (before June 2008, 17 months), whereas a stapler closure was planned in 22 consecutive patients in the 2nd period (after June 2008, 17 months). The 48 patients included 20 males and 28 females with an average age of 60.2 years (range: 15–83). The indications for surgery were pancreatic cancer in 24 patients, islet cell tumor in 9, intraductal papillary mucinous neoplasm in 5, mucinous cystic neoplasm in 3; direct invasion of malignant tumors to the pancreas in 3, solid pseudopapillary tumor in 2 and non-neoplastic lesions in 2.

Surgical Procedures

All pancreatic resections were performed in accordance with a standardized procedure by the same surgical team. A cut-line was selected in the proximal pancreas, near the portal vein in patients with pancreatic cancer, or 1 cm from the proximal margin of the tumor in patients with a noncancerous lesion. During the 1st period, the pancreas was cut by an electric knife using a cut mode, followed by a ligation of the main pancreatic duct with nonabsorbable sutures. After suturing the main duct, the cut surface was closed with single stitches that joined the ventral and dorsal edges of the pancreas according to the 'fish-mouth' technique. During the 2nd period, the pancreas was transected using the echelon 60 linear stapler (Ethicon Endo-Surgery; Johnson & Johnson, Tokyo, Japan). The closure jaw was clamped carefully and slowly, taking more than 5 min at a fixed speed [15]. All patients underwent a splenectomy. Two drainage tubes were placed at the pancreatic remnant and at the subphrenic space. Antibiotics were administered for 3 days after surgery, but somatostatin analogues were not used in any patient perioperatively. At the patients' discretion, a laparoscopic pancreatectomy was done in 2 patients, and a laparoscopy-assisted pancreatectomy was done in 6 patients. These surgical procedures were applied only to patients with benign tumors. Four patients who had a laparoscopy-assisted distal pancreatectomy in the 1st period underwent a hand-sewn closure, which was performed through the small upper-abdominal incision. In the 2nd period, 2 patients of laparoscopic distal pancreatectomy and 2 patients who had a laparoscopy-assisted distal pancreatectomy underwent a stapler closure. There were no conversions to open surgery.

Definition of Pancreatic Fistula

Pancreatic fistula was defined according to the criteria of the International Study Group on Pancreatic Fistula Definition [16]. In the present study, a grade B pancreatic fistula was defined as the postoperative pancreatic fistula because a change in management or adjustment in the clinical pathway is required in this grade. Briefly, the peripancreatic drains usually remain in place in a grade B fistula; however, if the drains are not able to fully drain the fistula, then a CT scan may show peripancreatic collection(s) requiring the repositioning of the drains. Antibiotics are usually required when a pancreatic fistula is associated with abdominal pain, fever and/or leukocytosis. The number of patients with a grade A or subclinical pancreatic fistula, which can be detected only by the biochemical analysis (any measurable volume of drain fluid with an amylase content greater than 3 times the upper normal serum value on or after postoperative day 3), was counted but not included in the pancreatic fistula. A grade C fistula was not observed in the present study.





Fig. 1. Measurement of the thickness of the pancreatic remnant by preoperative CT. In pancreatic transection at the body level (arrowheads), the thickness differs between the patients.

Clinical Characteristics

The cut-line of the pancreas was planned based on preoperative CT; however, the true cut-line was recorded during surgery and the thickness of the true pancreatic cut-line was measured postoperatively by preoperative CT using Centricity Enterprise software (version 3.0; GE Medical Systems, Tokyo, Japan; fig. 1). Regardless of the CT density of pancreatic parenchyma, a thick pancreas was retrospectively defined as more than 13 mm because the median thickness of all enrolled patients was 13 mm. The texture of the pancreatic parenchyma was defined as either soft or hard, according to the surgeon's judgment. The amylase concen-

trations in the peripheral blood and in the drain fluid were measured on postoperative days 1, 3 and 7.

Statistical Analyses and Ethical Considerations

All data were reported as the mean \pm SD and/or median. Fisher's exact test for categorical data and the Mann-Whitney U test for continuous data were used. Multiple logistic regression analysis was used to identify the independent risk factors for pancreatic fistula. Statistically significant factors by univariable analyses were entered into the multivariable model. For each variable, the OR with 95% CI was determined. Data analyses were performed based on an intention-to-treat basis using the SPSS software package (SPSS Inc., Chicago, Ill., USA), and a p value of less than 0.05 was considered to be statistically significant. The study protocol was approved by the Human Ethics Review Committee of Osaka University Graduate School of Medicine and a signed consent form was obtained from each patient.

Results

No statistical differences were observed between the hand-sewn group and the stapler group in the male/female ratio, age, indications for surgery, extent of pancreatic resection, percentage of laparoscopic or laparoscopy-assisted surgery, texture of the pancreas (soft or hard), thickness of the pancreas, amylase level in the drain fluid, or duration of postoperative hospital stay (table 1). All patients in the hand-sewn group successfully underwent a hand-sewn closure, while a stapler closure was impossible in 2 patients in the stapler group because the surgical cut-lines were too close to the gastroduodenal artery. A pancreatic fistula (grade B or C) was observed in 7 patients (27%) in the hand-sewn group, whereas 5 patients (23%) developed a pancreatic fistula in the stapler group ($p = \text{n.s.}$). Two patients in the stapler group in whom a staple closure failed did not develop a pancreatic fistula. The cartridge for stapler in the stapler group was chosen by the surgeon: a white cartridge (1 mm) was used in 2, blue (1.5 mm) in 2, gold (1.8 mm) in 11 and green (2 mm) in 5. The 5 patients that had a pancreatic fistula in the stapler group included patients treated with white (1 patient), gold (2 patients) and green cartridges (2 patients). A subclinical pancreatic fistula was observed in 22 patients (84.6%) in the hand-sewn group and 14 patients (63.6%) in the stapler group ($p = \text{n.s.}$). These subclinical pancreatic fistulas were not added to the following analyses. No patients died perioperatively.

The patients' characteristics were compared between the patients with a pancreatic fistula and those without a fistula in order to identify the risk factors for pancreatic fistula in all patients. Univariate analyses demon-

Table 1. Patient characteristics

	Hand-sewn group	Stapler group	P
Number of cases	26	22	
Gender, male:female	8:18	12:10	0.10
Age, years \pm SD	56.8 \pm 18.3	64.3 \pm 12.2	0.21
Indications, pancreatic cancer:other	11:15	13:9	0.25
Resection, body and tail:tail	19:7	21:1	0.06
Laparotomy:laparoscopy-assisted	22:4	18:4	>0.99
Soft pancreas:hard pancreas	19:7	18:4	0.47
Thickness, mm \pm SD	13.7 \pm 5.0	12.6 \pm 4.3	0.44
Pancreatic fistula, yes:no (%)	7:19 (27:73)	5:17 (23:77)	0.74
Amylase level in drain fluid, U/l \pm SD	5,937 \pm 15,423	2,062 \pm 4,225	0.13
Postoperative hospital stay, days	31.4 \pm 24.0	27.2 \pm 14.4	0.94

Table 2. Factors associated with postoperative pancreatic fistula in all patients (univariate analysis)

	Pancreatic fistula		P
	yes	no	
Number of cases	12	36	0.50
Gender, male:female	6:6	14:22	0.03*
Age, years \pm SD	53.0 \pm 13.4	62.6 \pm 16.4	0.18
Indications, pancreatic cancer:other	4:8	20:16	0.39
Resection, body and tail:tail	9:3	31:5	0.39
Laparotomy:laparoscopy-assisted	9:3	31:5	0.25
Soft pancreas:hard pancreas	11:1	26:10	0.003*
Thickness, mm \pm SD	16.7 \pm 4.4	12.0 \pm 4.2	0.74
Closure technique, hand-sewn:stapler	7:5	19:17	<0.0001*
Amylase level in drain fluid, U/l \pm SD	13,924 \pm 21,095	907 \pm 1,520	

* $p < 0.05$.

strated that patients' age ($p = 0.03$) and the thickness of the pancreatic remnant ($p = 0.003$) were significant factors (table 2). Neither the male/female ratio, indications for surgery, extent of pancreatic resection nor texture of the pancreas were different between the groups. By logistic regression analysis of risk factors for pancreatic fistula, younger age (OR = 0.949, $p = 0.048$) and the thickness of the pancreatic remnant (OR = 1.342, $p = 0.006$) were identified as independent risk factors (table 3).

Statistical analyses in all patients elucidated that a thick pancreas was one of the independent risk factors for pancreatic fistula; however, it is conceivable that a thick pancreas may be a more serious factor when the pancreatic remnant is closed by a stapler instead of a hand-sewn closure because a thick pancreas may be crushed when

Table 3. Logistic regression analysis of risk factors for pancreatic fistula

	OR	95% CI	P
Age, years	0.949	0.901–0.999	0.048*
Thickness, mm	1.342	1.090–1.652	0.006*

* $p < 0.05$.

compressed by a stapler. We therefore separately calculated risk factors for pancreatic fistula in patients who underwent hand-sewn closure (table 4) or stapler closure (table 5). Neither the male/female ratio, age, indications for surgery, extent of pancreatic resection, texture of the

Table 4. Factors associated with postoperative pancreatic fistula in patients who underwent hand-sewn closure

	Pancreatic fistula		P
	yes	no	
Number of cases	7	19	
Gender, male:female	4:3	4:15	0.15
Age, years \pm SD	49.9 \pm 16.6	59.3 \pm 18.7	0.24
Indications, pancreatic cancer:other	2:5	9:10	0.66
Resection, body and tail:tail	5:2	14:5	0.99
Laparotomy:laparoscopy-assisted	4:3	18:1	0.047*
Soft pancreas:hard pancreas	7:0	12:7	0.13
Thickness, mm \pm SD	15.9 \pm 5.6	12.9 \pm 4.7	0.21
Amylase level in drain fluid, U/l \pm SD	18,846 \pm 26,773	1,182 \pm 1,666	0.0002*

* p < 0.05.

Table 5. Factors associated with postoperative pancreatic fistula in patients who underwent stapler closure

	Pancreatic fistula		P
	yes	no	
Number of cases	5	17	
Gender, male:female	2:3	10:7	0.62
Age, years \pm SD	57.4 \pm 6.3	66.4 \pm 12.8	0.05
Indications, pancreatic cancer:other	2:3	11:6	0.61
Resection, body and tail:tail	4:1	17:0	0.23
Laparotomy:laparoscopy-assisted	5:0	13:4	0.54
Soft pancreas:hard pancreas	4:1	14:3	>0.99
Thickness, mm \pm SD	17.8 \pm 2.3	11.1 \pm 3.4	0.002*
Amylase level in drain fluid, U/l \pm SD	7,033 \pm 6,840	600 \pm 1,319	0.002*

* p < 0.05.

pancreas nor thickness of the pancreas were different between the groups in the hand-sewn group. In the hand-sewn closure group, 3 of 4 patients who underwent a laparoscopy-assisted pancreatectomy developed a pancreatic fistula, which was statistically higher than those who underwent a conventional pancreatectomy ($p = 0.047$). The amylase level in patients with a pancreatic fistula was $18,846 \pm 26,773$ U/l, but was $1,182 \pm 1,666$ U/l in those without a fistula ($p = 0.0002$). In the stapler group, the thickness of the pancreatic remnant was statistically greater in patients with a pancreatic fistula than those without a fistula ($p = 0.002$; table 5). There was no difference associated with the male/female ratio, age, indications for surgery, extent of pancreatic resection, percentage of laparoscopic or laparoscopy-assisted surgery, or

texture of the pancreas. The amylase level in patients with a pancreatic fistula was higher than that in those without a fistula ($p = 0.002$). Even when 2 patients in whom a stapler closure was unsuccessful were excluded from these analyses, the thickness and the amylase level were still statistically higher in patients with a pancreatic fistula ($p = 0.002$ and 0.003 , respectively).

Figure 2 shows the relationship between the thickness of the pancreatic remnant and the presence or absence of a pancreatic fistula. None of the patients in the stapler group with a thin pancreatic remnant (13 mm or less) developed a pancreatic fistula, whereas 50% of patients with a thicker remnant (more than 13 mm) developed a fistula, which was statistically significant by intention-to-treat analysis ($p = 0.01$). This difference was still statisti-

cally significant when 2 patients in whom a staple closure failed were excluded ($p = 0.008$). The incidence of fistula in patients in the hand-sewn group with a thick remnant was 38%, which was lower than those with thick remnants in the stapler group, although not statistically significant.

Discussion

The present study retrospectively investigated the risk factors for pancreatic fistula and identified that younger age and a thick pancreas were independent risk factors. Patient age has been reported as an independent risk factor, but thickness has not yet been discussed so far. Moreover, previous studies include several kinds of closure techniques, such as hand-sewn and stapling techniques, and therefore the true risk factors of using a stapler remain to be elucidated. Surgeons speculate that a thick and hard pancreas is more likely to be crushed when compressed by a stapler; nevertheless, no investigation to confirm this hypothesis has yet been carried out. The present study revealed that 50% of patients with a thick pancreas developed a pancreatic fistula when the pancreatic remnant is closed by a stapler, while no patients with a thin pancreas developed this. The results indicate that patients with a thin pancreas should be recommended to undergo a stapler closure while a thick pancreas is a risk factor for pancreatic fistula regardless of the closure techniques.

Both previous studies and the current results also indicated that the hand-sewn closure of a hard pancreas was less likely to induce a pancreatic fistula (no cases in 7; table 2) than a soft pancreas (7 cases in 19), although this difference was not statistically significant. Although the initial hypothesis was that a hard pancreas would be more likely to be crushed when compressed by a stapler, the current results indicate the same incidence of pancreatic fistula in patients with a soft pancreas as observed in those with a hard pancreas when the stapler is used (table 5). There is insufficient evidence to propose an underlying mechanism for this observation; however, the equal incidence may result from the fact that the accompanying pancreatitis in a distal pancreatectomy is generally less severe than in a pancreaticoduodenectomy, so that the pancreas can be compressed even when it is diagnosed to be hard.

Okano et al. [15] noted that the most important and technically difficult step of a stapler dissection was to prevent the pancreatic tissue from tearing during compres-




Fig. 2. Distribution of patients according to thickness and closing techniques. Closed circles indicate patients with pancreatic fistula. Two patients in whom a staple closure failed in the stapler group did not develop pancreatic fistula (double circles).

sion. Therefore, they clamped the stapler jaw carefully and slowly over more than 5 min at a fixed speed. The procedures in the present study clamped the stapler in the same manner. Even with this careful procedure, the result clearly confirmed that patients with a thick pancreas had a higher risk for pancreatic fistula. It is unclear why a thick pancreas, but not a hard pancreas, is a risk factor for pancreatic fistula. Macroscopically, the serosa of the pancreatic remnant was intact just after stapling in all these cases. Thereafter either microscopic tissue tearing during surgery or delayed tearing after surgery may occur if the remnant is too thick.

It is also unclear if the selection of the cartridge for stapler has any influence on the outcome. In the present study, 1 patient whose pancreas was closed by a stapler with a white cartridge developed a pancreatic fistula. It is not yet clarified whether that the selection of the cartridge can be a very important determinant for inducing a pancreatic fistula; therefore, it should be elucidated by a prospective study. Nevertheless, except for 1 patient, all patients with a thick pancreas in the stapler group were treated using a cartridge of greater staple height (green cartridge or gold cartridge) in order to avoid compression which is too strong. Even with these selections, however, the incidence of pancreatic fistula was high in patients with a thick pancreas, indicating that the thickness itself is the risk factor for pancreatic fistula, at least when employing currently available stapling devices. Moreover,

we should note that 2 patients who had been scheduled for stapler closure could not be stapled because their surgical cut-lines were too close to the gastroduodenal artery. Fortunately, these 2 patients underwent a hand-sewn closure and did not develop a pancreatic fistula; however, a hand-sewn closure is also difficult to such patients. Another closure technique should be established for such patients.

In the present study, 8 patients underwent laparoscopic or laparoscopy-assisted distal pancreatectomy. Although these surgical procedures were not identified as risk factors for pancreatic fistula, it should be noted that 3 out of 4 patients who underwent a laparoscopy-assisted hand-sewn closure developed a pancreatic fistula. This higher incidence may have been caused by a surgically inappropriate procedure, as a laparoscopy-assisted hand-sewn closure was performed through the very small upper-abdominal incision.

The present study defined 13 mm as the cutoff value because 13 mm was the median thickness in this series of patients and it was concluded that a thick pancreas of more than 13 mm was a risk factor for pancreatic fistula. However, a true cutoff value still remains to be determined, which requires evaluating a larger number of patients.

In summary, this study clarifies that a thick pancreas, but not a hard pancreas, is one of the risk factors for a postoperative pancreatic fistula regardless of the closure technique and that patients with a thick pancreas have a higher risk of pancreatic fistula than those with a thin pancreas when the pancreatic remnant is closed by a stapler. A randomized clinical trial with a large number of patients to confirm these findings is suggested, as well as the identification of an appropriate cutoff value for the thickness of the pancreas for which a stapler can be safely used.

References

- Nathan H, Cameron JL, Goodwin CR, Seth AK, Edil BH, Wolfgang CL, Pawlik TM, Schulick RD, Choti MA: Risk factors for pancreatic leak after distal pancreatectomy. *Ann Surg* 2009;250:277-281.
- Kleeff J, Diener MK, Z'Graggen K, Hinz U, Wagner M, Bachmann J, Zehetner J, Muller MW, Friess H, Buchler MW: Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. *Ann Surg* 2007;245:573-582.
- Ridolfini MP, Alfieri S, Gourgiotis S, Di Miceli D, Rotondi F, Quero G, Manghi R, Doglietto GB: Risk factors associated with pancreatic fistula after distal pancreatectomy, which technique of pancreatic stump closure is more beneficial? *World J Gastroenterol* 2007;13:5096-5100.
- Pannegeon V, Pessaux P, Sauvanet A, Vullierme MP, Kianmanesh R, Belghiti J: Pancreatic fistula after distal pancreatectomy: predictive risk factors and value of conservative treatment. *Arch Surg* 2006;141:1071-1076.
- Balzano G, Zerbi A, Cristallo M, Di Carlo V: The unsolved problem of fistula after left pancreatectomy: the benefit of cautious drain management. *J Gastrointest Surg* 2005;9:837-842.
- Fahy BN, Frey CF, Ho HS, Beckett L, Bold RJ: Morbidity, mortality, and technical factors of distal pancreatectomy. *Am J Surg* 2002;183:237-241.
- Sheehan MK, Beck K, Creech S, Pickleman J, Aranha GV: Distal pancreatectomy: does the method of closure influence fistula formation? *Am Surg* 2002;68:264-268.
- Bassi C, Salvia R, Butturini G, Marcucci S, Barugola G, Falconi M: Prospective randomized pilot study of management of the pancreatic stump following distal resection. *HPB (Oxford)* 1999;1:203-207.
- Sledzianowski JF, Duffas JP, Muscari F, Suc B, Fourtanier F: Risk factors for mortality and intra-abdominal morbidity after distal pancreatectomy. *Surgery* 2005;137:180-185.
- Suzuki Y, Fujino Y, Tanioka Y, Hori Y, Ueda T, Takeyama Y, Tominaga M, Ku Y, Yamamoto YM, Kuroda Y: Randomized clinical trial of ultrasonic dissector or conventional division in distal pancreatectomy for non-fibrotic pancreas. *Br J Surg* 1999;86:608-611.
- Olah A, Issekutz A, Belagyi T, Hajdu N, Romics L Jr: Randomized clinical trial of techniques for closure of the pancreatic remnant following distal pancreatectomy. *Br J Surg* 2009;96:602-607.
- Wagner M, Gloor B, Ambuhl M, Worni M, Lutz JA, Angst E, Candinas D: Roux-en-Y drainage of the pancreatic stump decreases pancreatic fistula after distal pancreatic resection. *J Gastrointest Surg* 2007;11:303-308.
- Knaebel HP, Diener MK, Wente MN, Buchler MW, Seiler CM: Systematic review and meta-analysis of technique for closure of the pancreatic remnant after distal pancreatectomy. *Br J Surg* 2005;92:539-546.
- Diener MK, Knaebel HP, Witte ST, Rossion I, Kieser M, Buchler MW, Seiler CM: DISTAL PACT trial: a randomized controlled trial to compare two different surgical techniques of DISTAL PANCREATECTOMY - study rationale and design. *Clin Trials* 2008;5:534-545.
- Okano K, Kakinoki K, Yachida S, Izuishi K, Wakabayashi H, Suzuki Y: A simple and safe pancreas transection using a stapling device for a distal pancreatectomy. *J Hepatobiliary Pancreat Surg* 2008;15:353-358.
- Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, Neoptolemos J, Sarr M, Traverso W, Buchler M: Postoperative pancreatic fistula: an international study group (ISGPF) definition. *Surgery* 2005;138:8-13.

Advantage of autologous blood transfusion in surgery for hepatocellular carcinoma

Yoshito Tomimaru, Hidetoshi Eguchi, Shigeru Marubashi, Hiroshi Wada, Shogo Kobayashi, Masahiro Tanemura, Koji Umeshita, Yuichiro Doki, Masaki Mori, Hiroaki Nagano

Yoshito Tomimaru, Hidetoshi Eguchi, Shigeru Marubashi, Hiroshi Wada, Shogo Kobayashi, Masahiro Tanemura, Koji Umeshita, Yuichiro Doki, Masaki Mori, Hiroaki Nagano, Department of Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Osaka, Japan
Koji Umeshita, Division of Health Sciences, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Osaka, Japan

Author contributions: Tomimaru Y was responsible for the review of the literature and initial preparation of the paper; Eguchi H, Marubashi S, Wada H, Kobayashi S, Tanemura M, and Umeshita K supported the preparation; Doki Y, Mori M, and Nagano H prepared the final version of the manuscript.

Correspondence to: Hiroaki Nagano, MD, PhD, Department of Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka E-2, Suita 565-0871, Osaka, Japan. hnagano@gesurg.med.osaka-u.ac.jp

Telephone: +81-6-6879-3251 Fax: +81-6-6879-3259

Received: October 12, 2010 Revised: November 17, 2010

Accepted: November 24, 2010

Published online: August 28, 2011

Abstract

AIM: To evaluate the significance of autologous blood transfusion (AT) in reducing homologous blood transfusion (HT) in surgery for hepatocellular carcinoma (HCC).

METHODS: The proportion of patients who received HT was compared between two groups determined by the time of AT introduction; period A (1991-1994, $n = 93$) and period B (1995-2000, $n = 201$). Multivariate logistic regression analysis was performed in order to identify independent significant predictors of the need for HT. We also investigated the impact of AT and HT on long-term postoperative outcome after curative surgery for HCC.

RESULTS: The proportion of patients with HT was

significantly lower in period B than period A (18.9% vs 60.2%, $P < 0.0001$). Multivariate logistic regression analysis identified AT administration as a significant independent predictor of the need for HT ($P < 0.0001$). Disease-free survival in patients with AT was comparable to that without any transfusion. Multivariate analysis identified HT administration as an independent significant factor for poorer disease-free survival ($P = 0.0380$).

CONCLUSION: AT administration significantly decreased the need for HT. Considering the postoperative survival disadvantage of HT, AT administration could improve the long-term outcome of HCC patients.

© 2011 Baishideng. All rights reserved.

Key words: Hepatocellular carcinoma; Surgery; Autologous blood transfusion; Homologous blood transfusion

Peer reviewer: Dr. Assy Nimer, MD, Assistant Professor, Liver Unit, Ziv Medical Centre, BOX 1008, Safed 13100, Israel

Tomimaru Y, Eguchi H, Marubashi S, Wada H, Kobayashi S, Tanemura M, Umeshita K, Doki Y, Mori M, Nagano H. Advantage of autologous blood transfusion in surgery for hepatocellular carcinoma. *World J Gastroenterol* 2011; 17(32): 3709-3715 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v17/i32/3709.htm> DOI: <http://dx.doi.org/10.3748/wjg.v17.i32.3709>

INTRODUCTION

Surgical resection is a safe and effective treatment for hepatocellular carcinoma (HCC). Because HCC usually develops in patients with liver cirrhosis, most of such patients present with bleeding tendencies related to

chronic liver dysfunction^[1-3]. Therefore, surgery for HCC frequently requires intraoperative transfusion. Homologous blood transfusion (HT) is necessary for patients with excessive intraoperative bleeding, though this is still associated with risks of infections and/or immunological complications^[4,5]. Moreover, evidence suggests that HT may be adversely associated with tumor recurrence and poor postoperative survival in various kinds of cancers^[6-13]. Autologous transfusion (AT), which represents collection and reinfusion of the patient's own blood or blood components before surgery, and has been developed as a strategy to reduce the need for HT, is currently used for patients scheduled for surgery for various diseases including HCC^[11,14-17]. It has been the policy in our hospital since 1995 to prepare for AT for patients scheduled for HCC surgery. To date, several investigators have examined the significance of AT in terms of reducing the need for HT and of postoperative outcome, but only a few were conducted with proper statistical analyses to identify the significance of AT^[16,17].

In the present study, we reviewed the frequency of HT and AT administration in patients undergoing surgery for HCC, and statistically analyzed the significant factors that could predict the need for HT. We also compared the difference between the effects of AT and HT on long-term postoperative outcome after curative surgery for HCC.

MATERIALS AND METHODS

The present study included 294 patients with HCC who underwent hepatic resection at the Department of Surgery, Osaka University Hospital between January 1991 and December 2000. In 93 patients between 1991 and 1994 (period A), AT was not administered, and, when blood was needed, HT was administered. Between 1995 and 2000 (period B), AT was carried out preoperatively in the remaining 201 patients provided: (1) they agreed to the storage; (2) their hemoglobin (Hb) level was ≥ 11.0 g/dL before storage; and (3) they were free of severe cardiopulmonary and/or cerebrovascular diseases, or infection. Autologous blood was collected 1 to 3 times, with 200-400 mL of blood at a time. The blood was stored in a liquid state without freezing. Iron supplements were given daily to the patients who deposited the autologous blood in the post-storage period. In addition, if the total volume of the collected blood was ≥ 800 mL, recombinant human erythropoietin was administered. All through the study period, during hepatic resection, blood transfusion was carried out when the Hb level fell to < 8.0 g/dL in patients with normal cardiopulmonary function or < 9.0 g/dL in patients with severe cardiopulmonary or cerebrovascular diseases. In patients who had previously deposited autologous blood, autologous blood was first used prior to homologous blood. In this study, patients who required HT were defined as the HT group, irrespective of prior AT, and the remaining patients without HT were defined as the non-HT group.

Furthermore, patients in whom only AT was performed were defined as the AT group, and patients without AT or HT were as defined as the non-transfusion group.

Hospital records were collected retrospectively to gather clinical information including clinical factors, tumor-related factors and surgery-related factors. In patients with autologous blood storage, preoperative Hb was indicated as Hb before the storage. The surgical procedure was selected based on the extent of the tumor and residual liver function. The indication for surgery and selection of surgical procedure were not different between period A and period B. The histological grade of differentiation of HCC was determined according to the Edmondson-Steiner classification, and was based on the areas of the tumor with the highest grade^[18]. Data were expressed as mean \pm standard deviation. Differences between groups were assessed by the chi-square test, Fisher's exact test or the Mann-Whitney *U* test. Survival rates were calculated according to the Kaplan-Meier method, and compared using the log-rank test. Multivariate logistic regression analysis was performed for the selection of significant variables. Statistical analysis was performed using StatView (version 5.0; SAS Institute Inc., Cary, NC). A *P* value < 0.05 was considered significant. The study protocol was approved by the Human Ethics Review Committee of Osaka University Hospital and a signed consent form was obtained from each patient.

RESULTS

Table 1 shows the clinicopathological characteristics of patients in period A ($n = 93$) and in period B ($n = 201$). The clinical features, tumor-related features, and surgery-related factors were not significantly different between patients of the 2 groups. HT was administered in 56 of the 93 patients (60.2%) in period A. In period B, HT was administered in 38 patients (18.9%) (HT group), AT in 134 patients (66.7%), and neither AT nor HT in 45 patients (22.4%) (non-transfusion group). In 134 AT patients, the amount of transfused autologous blood was 200 mL in 3 patients, 400 mL in 63 patients, 600 mL in 2 patients, 800 mL in 62 patients, 1000 mL in 1 patient, and 1200 mL in 3 patients. Among the 134 patients with AT, only AT was administered in 118 patients (58.7%) (AT group), and both AT and HT in the remaining 16 patients (8.0%). Figure 1 shows the distribution of patients according to blood transfusion. Thus, the proportion of patients who received HT was significantly lower in period B than in period A ($P < 0.0001$). With regard to disease-free survival examined only in patients with curative surgery for HCC, there were no significant differences between period A and period B; the 1-, 3-, 5-, and 10-year disease-free survival rates were 73.9%, 39.5%, 24.7%, and 7.2% for patients in period A, and 65.9%, 34.8%, 21.9%, and 7.2% for patients in period B ($P = 0.5688$), respectively. The 1-, 3-, 5- and 10-year overall survival rates were 85.7%, 75.6%, 63.1%, and 28.5% for patients in period A, and 92.9%, 70.6%,

Table 1 Clinicopathological characteristics of patients of periods A and B with hepatocellular carcinoma

	Period A (1991-1994) (n = 93)	Period B (1995-2000) (n = 201)	P-value
Clinical factors			
Gender (male/female)	81/12	161/40	0.144
Age (yr) ¹	61 ± 9	62 ± 9	0.102
HBs-Ag (±)	73/20	169/32	0.243
Anti-HCV Ab (±/unknown)	29/62/2	71/125/5	0.471
Child-Pugh classification (A/B)	79/14	160/41	0.275
Preoperative Hb (g/dL) ¹	13.6 ± 1.5	13.3 ± 1.6	0.213
Tumor-related factors			
Number of tumors (single/multiple)	70/23	146/55	0.635
Maximum tumor size (cm) ¹	3.8 ± 2.7	4.1 ± 3.1	0.450
Vascular invasion (±)	83/10	172/29	0.388
Histological grade (I, II/III, IV/unknown)	40/41/12	89/92/20	0.975
Surgery-related factors			
Procedure (nonanatomical/anatomical)	45/48	101/100	0.767
Operation time (min) ¹	291 ± 144	295 ± 151	0.853
Resected liver volume (g) ¹	218 ± 406	214 ± 289	0.925
Intraoperative blood loss (mL) ¹	2190 ± 5689	1621 ± 2209	0.219

¹Data are expressed as number of patients and mean ± standard deviation. HBs-Ag: Hepatitis B surface antigen; Anti-HCV Ab: Anti-hepatic C virus antibody; Hb: Hemoglobin.

Table 2 Clinicopathological characteristics of patients with hepatocellular carcinoma according to homologous blood transfusion

	Non-HT group (n = 200)	HT group (n = 94)	P-value
Clinical factors			
Gender (male/female)	162/38	80/14	0.390
Age (yr) ¹	62 ± 9	60 ± 9	0.084
HBs-Ag (±)	168/32	74/20	0.269
Anti-HCV Ab (±/unknown)	65/130/5	35/57/2	0.437
Child-Pugh classification (A/B)	167/33	72/22	0.157
Preoperative Hb (g/dL) ¹	13.5 ± 1.6	13.2 ± 1.7	0.171
AT administration (±)	82/118	78/16	< 0.0001
Tumor-related factors			
Number of tumors (single/multiple)	149/51	67/27	0.559
Maximum tumor size (cm) ¹	3.6 ± 2.4	4.9 ± 3.7	0.000
Vascular invasion (±)	177/23	78/16	0.193
Histological grade (I, II/III, IV/unknown)	91/88/21	38/45/11	0.446
Surgery-related factors			
Procedure (nonanatomical/anatomical)	111/89	35/59	0.004
Operation time (min) ¹	264 ± 130	356 ± 166	< 0.0001
Resected liver volume (g) ¹	159 ± 196	336 ± 490	< 0.0001
Intraoperative blood loss (mL) ¹	993 ± 707	3522 ± 6104	< 0.0001

¹Data are expressed as number of patients and mean ± standard deviation. HBs-Ag: Hepatitis B surface antigen; Anti-HCV Ab: Anti-hepatic C virus antibody; Hb: Hemoglobin; AT: Autologous transfusion; HT: Homologous transfusion.

58.2%, and 40.3% for patients in period B ($P = 0.3202$).




Figure 1 Distribution of patients according to transfusion status during periods A and B. The proportion of patients who received HT was significantly lower in period B than period A ($P < 0.0001$). AT: Autologous transfusion; HT: Homologous transfusion.

In order to identify the factors that can predict the need for HT, various clinical parameters, tumor-related factors, and surgery-related factors were compared between the non-HT group and the HT group (Table 2). The preoperative Hb level was not significantly different between the 2 groups (13.5 ± 1.6 g/dL *vs* 13.2 ± 1.7 g/dL, $P = 0.1708$). The proportion of patients who received AT was significantly lower in the HT group than the non-HT group [59.0% ($118/200$) *vs* 17.0% ($16/94$), $P < 0.0001$]. The maximum tumor size was significantly larger in the HT group than in the non-HT group (4.9 ± 3.7 cm *vs* 3.6 ± 2.4 cm, $P = 0.0003$). As for surgery-related factors, there were significant differences in surgical procedure ($P = 0.0035$), operation time ($P < 0.0001$), resected liver volume ($P < 0.0001$), and intraoperative blood loss ($P < 0.0001$), suggesting that surgery in the HT group was major compared to that in the non-HT group.

To identify significant factors that could predict the need for HT, multivariate logistic regression analysis was performed (Table 3). The analysis was carried out using the 6 significant factors identified in the comparison of the non-HT group and the HT group. The analysis identified AT administration, intraoperative blood loss, and resected liver volume as significant independent predictors for the need of HT ($P < 0.0001$, $P < 0.0001$, $P = 0.0362$, respectively). Long-term postoperative outcome after surgery for HCC was examined. In this analysis, patients were limited to those with curative resection, which was defined as complete removal of all macroscopically evident tumors [non-HT group: 193 patients (non-transfusion group: 78 patients; AT group: 115 patients), HT group: 83 patients]. Among the 276 patients, 37 patients (13.4%) were followed-up for more than 10 years. The clinicopathological features of the groups are shown in Table 4. First, we compared the long-term postoperative outcome between the non-transfusion group and the AT group. The preoperative Hb level was significantly higher in the AT group than in the non-

Table 3 Results of multivariate logistic regression analysis for the need for homologous blood transfusion

		OR	95% CI	P-value
AT administration	±	28.571	9.615-83.333	< 0.0001
Maximum tumor size (cm)	< 5/≥ 5	1.126	0.500-2.538	0.774
Procedure	Nonanatomical/anatomical	1.016	0.449-2.202	0.967
Operation time (min)	< 300/≥ 300	0.986	0.435-2.242	0.974
Resected liver volume (g)	< 200/≥ 200	2.532	1.062-6.061	0.036
Intraoperative blood loss (mL)	< 2000/≥ 2000	30.303	9.346-100.000	< 0.0001

OR: Odds ratio; CI: Confidence interval; AT: Autologous transfusion.

Table 4 Clinicopathological characteristics of patients who underwent curative surgery for hepatocellular carcinoma

	Non-HT group (n = 193)	HT group (n = 83)	P-value (Non-HT vs HT)	Non-HT group		P-value (Non-transfusion vs AT)
				Non-transfusion group (n = 78)	AT group (n = 115)	
Clinical factors						
Gender (male/female)	156/37	70/13	0.488	63/15	93/22	0.986
Age (yr) ¹	62 ± 8	61 ± 9	0.115	62 ± 8	61 ± 9	0.878
HBs-Ag (±)	163/30	67/16	0.445	Nov-67	96/19	0.649
Anti-HCV Ab (±/unknown)	62/127/4	31/51/1	0.426	21/54/3	41/73/1	0.254
Child-Pugh classification (A/B)	161/32	65/18	0.262	66/12	95/20	0.833
Preoperative Hb (g/dL) ¹	13.5 ± 1.5	13.4 ± 1.6	0.425	12.8 ± 1.8	14.1 ± 1.1	< 0.0001
Tumor-related factors						
Number of tumors (single/multiple)	147/46	64/19	0.866	62/16	85/30	0.372
Maximum tumor size (cm) ¹	3.5 ± 2.4	4.8 ± 3.7	0.000	3.3 ± 2.2	3.6 ± 2.4	0.287
Vascular invasion (±)	172/21	70/13	0.268	73/5	99/16	0.101
Histological grade (I, II/III, IV/unknown)	89/83/21	33/41/9	0.304	36/34/8	53/49/13	0.412

¹Data are expressed as number of patients and mean ± standard deviation. HBs-Ag: Hepatitis B surface antigen; Anti-HCV Ab: Anti-hepatic C virus antibody; Hb: Hemoglobin; AT: Autologous transfusion; HT: Homologous transfusion.

transfusion group (14.1 ± 1.1 g/dL *vs* 12.8 ± 1.8 g/dL, $P < 0.0001$). Tumor-related factors were similar in the 2 groups. There were no significant differences in the disease-free survival rates between the AT group (1-, 3-, 5-, and 10-year: 70.6%, 37.1%, 22.3%, and 11.2%, respectively) and the non-transfusion group (73.1%, 41.3%, 30.7%, and 9.6%, respectively) ($P = 0.3874$) (Figure 2A). Next, we compared the long-term survival rates of the non-HT group and the HT group. Although the cumulative disease-free survival rate of the non-HT group was significantly better than that of the HT group ($P = 0.0305$) (Figure 2B), since the maximum tumor size was significantly different in the comparison (3.5 ± 2.4 cm *vs* 4.8 ± 3.7 cm, $P = 0.0004$), additional comparison was also performed based on the tumor size. The disease-free survival rates for the non-HT group (1-, 3-, 5-, and 10-year: 75.6%, 42.6%, 29.4%, and 10.8%, respectively) was significantly better than those of the HT group (69.0%, 31.6%, 16.7%, and 4.5%, respectively) of the subgroup with tumor size 5.0 cm or smaller than 5.0 cm ($P = 0.0452$) (Figure 2C), but not in patients with tumor size larger than 5.0 cm (1-, 3-, 5-, and 10-year: 56.4%, 24.1%, 10.8%, and 5.4% in the non-HT group, and 39.4%, 26.3%, 13.1%, and 0.0% in the HT group, respectively, $P = 0.7391$) (Figure 2D). Furthermore, multivariate analyses using significant factors identified in the univariate analyses demonstrated that transfusion status (non-HT/HT) was one of the independent significant factors for disease-free survival ($P = 0.0380$) (Table 5), suggest-

ing disadvantages of HT on postoperative prognosis.

DISCUSSION

The results of the present study demonstrated a reduction in HT administration in surgery for HCC after the introduction of AT. Our results are in agreement with those of previous reports which emphasized the significance of AT in reducing the need for HT in surgery for HCC^{16,17}. However, in these previous reports, only 20-30 patients were included in the AT group. Furthermore, although the Hb level immediately before surgery was reported in the AT group, the Hb level before storage was not indicated, suggesting a different clinical background of patients who received HT and those of other groups. On the other hand, in the present study, despite its retrospective design, the clinicopathological background, including the Hb level, was similar in the 2 groups as shown in Table 1. In this regard, the present study is significant as it identified the benefits of AT in the reduction of HT administration.

In the present study, we analyzed the data for significant predictors of HT use. The results showed that AT administration was an independent significant predictor of the need for HT, and support the significance of AT in reducing the need for HT. In the analysis, preoperative Hb, which is reported to be significantly associated with the need for HT^{19,20}, was not an independent significant factor. While the reason for this difference in the results




Figure 2 Disease-free survival after curative surgery for hepatocellular carcinoma. A: There were no significant differences between the non-transfusion group (solid line) and the Autologous transfusion (AT) group (dotted line) ($P = 0.3874$); B: The cumulative disease-free survival in the non-Homologous transfusion (HT) group (solid line) was significantly better than in the HT group (dotted line) ($^aP = 0.0305$); C: The disease-free survival in the non-HT group (solid line) was significantly better in than the HT group (dotted line) in patients with maximum tumor size of ≤ 5.0 cm ($^aP = 0.0452$); D: No significant differences were noted between the non-HT group (solid line) and the HT group (dotted line) in patients with the maximum tumor size > 5.0 cm ($P = 0.7391$).

Table 5 Statistical analysis of disease-free survival of patients with curative resection for hepatocellular carcinoma

	Univariate		Multivariate	
	P-value	OR	95% CI	P-value
Clinical factors				
Gender (male/female)	0.840			
Age (yr) (≤ 63 / > 63)	0.402			
HBs-Ag (\pm)	0.279			
Anti-HCV Ab (\pm)	0.045	1.401	1.032-1.901	0.031
Child-Pugh classification (A/B)	0.079			
Preoperative Hb (g/dL)	0.824			
(≤ 12 / > 12)				
Transfusion	0.031	1.372	1.018-1.849	0.038
(non-HT group/HT group)				
Tumor-related factors				
Number of tumors	0.000	1.819	1.290-2.564	0.001
(single/multiple)				
Maximum tumor size (cm)	0.001	1.07	0.750-1.525	0.709
(≤ 5 / > 5)				
Vascular invasion (\pm)	< 0.0001	2.473	1.606-3.806	< 0.0001
Histological grade (I, II/III, IV)	0.017	1.188	0.898-1.570	0.227

OR: Odds ratio; CI: Confidence interval; HBs-Ag: Hepatitis B surface antigen; Anti-HCV Ab: Anti-hepatic C virus antibody; Hb: Hemoglobin; HT: Homologous transfusion.

remains unclear, it could be due to the effect of recombinant human erythropoietin administered after the storage of autologous blood. Alternatively, it is possible that, since the subjects of the above previous studies did not receive AT, the significance of preoperative Hb is overestimated. Thus, the present study is significant in terms of identifying the effect of AT in reducing HT using appropriate statistical analysis.

We also investigated the effects of AT and HT on postoperative outcome after curative surgery for HCC. The study revealed that the disease-free survival rates were comparable between the non-transfusion group and the AT group when the clinical background was similar. Furthermore, the disease-free survival rates of the HT group were significantly worse than those of the non-HT group, based on the results of univariate analysis. Since there was a significant difference in the maximum tumor size between the 2 groups, which suggests the possibility of different tumor biology and recurrences between the HT group and the non-HT group, the survival rate was compared in subgroups based on tumor size, and showed significant differences in the pa-

tients with tumor size ≤ 5.0 cm. In addition, the difference was confirmed to be independently significant by multivariate analyses.

Since the report of a survival advantage of HT in patients undergoing colectomy for colon cancer^[21], some investigators have indicated that HT triggers recurrence in various kinds of cancers^[6-8]. This HT-induced disadvantage is speculated to be derived from transfusion-associated immunomodulation. Actually, several investigators suggested that HT induces downregulation of natural killer cell activity and cytotoxic T-cell function, resulting in a subclinical state of anergy or tolerance^[22-24].

The correlation has been reported also in patients with HCC^[9-14,25]. Although the results of the present study were comparable to these previous reports, we think that the present study reports a new finding based on the inclusion of patients who were followed-up for more than 10 years. With regard to the long-term survival advantages, to our knowledge, there are only a few reports describing the survival advantage of HT on long-term prognosis (> 10 years). Hirano *et al.*^[14] investigated the long-term (> 10 years) survival disadvantage of HT over AT, but their reports did not include the clinical background of patients and described the results of only univariate analysis, suggesting inadequate analysis. Also in this regard, the present study provides significant data.

Thus, the present study revealed that AT is significant in reducing the need for HT, which is associated with a long-term postoperative survival disadvantage after HCC surgery. In this study, however, in order to investigate the long-term postoperative outcome for more than 10 years, we limited inclusion in the study to patients who underwent surgery between 1991 and 2000. Based on this limitation, it is possible that the selected time period does not reflect recent advances in both surgical and anesthetic techniques, which could explain the recent decrease in intraoperative blood loss. Considering such recent advances affecting intraoperative blood loss, one can speculate that there are increasingly more patients with HCC who do not need AT. It was also reported recently that the practice of using autologous blood requires more administrative work and laborious collection procedures, and is not without disadvantages^[26-29]. Taken together, AT actually has advantage over HT, but currently, it may be necessary to deliberate on the need for AT itself during surgery for HCC.

In summary, the present study showed that AT administration significantly decreased the need for HT in surgery for HCC, and that AT was one of the significant independent predictor of the need for HT. Considering that HT was disadvantageous with regard to long-term postoperative survival, one can assume that AT administration can lead to improvement in the long-term postoperative outcome of patients with HCC.

COMMENTS

Background

Some evidences suggest that homologous blood transfusion (HT) may be

adversely associated with tumor recurrence and poor survival in various kinds of cancers, and autologous blood transfusion (AT) is currently used for patients scheduled for surgery. To date, several investigators have examined the significance of AT in terms of reducing the need for HT and postoperative outcome, but few were conducted with proper statistical analyses to identify the significance of AT in surgery for hepatocellular carcinoma (HCC).

Research frontiers

The authors compared the proportion of patients who received HT between 2 groups determined by the time of AT introduction; period A (1991-1994, $n = 93$) and period B (1995-2000, $n = 201$), and performed multivariate logistic regression analysis for identification of independent significant predictors of the need for HT. Furthermore, they investigated the impact of AT and HT on long-term postoperative outcome after curative surgery for HCC.

Innovations and breakthroughs

The present study showed that the proportion of patients having HT was decreased after AT introduction, that AT administration was a significant independent predictor of the need for HT, and identified HT administration as an independent significant factor for poorer disease-free survival.

Applications

Considering the results of the present study, it could be suggested that AT administration could improve the long-term outcome of patients with HCC.

Peer review

This is a large series of patients treated in several ways with respect to the need for blood transfusion during their surgery for HCC. Unfortunately the authors have a mix of numbers that they have used in different ways to make the conclusion they wanted to make.

REFERENCES

- 1 Hsia CY, Lui WY, Chau GY, King KL, Loong CC, Wu CW. Perioperative safety and prognosis in hepatocellular carcinoma patients with impaired liver function. *J Am Coll Surg* 2000; **190**: 574-579
- 2 Wu CC, Kang SM, Ho WM, Tang JS, Yeh DC, Liu TJ, P'eng FK. Prediction and limitation of hepatic tumor resection without blood transfusion in cirrhotic patients. *Arch Surg* 1998; **133**: 1007-1010
- 3 Farges O, Malassagne B, Flejou JF, Balzan S, Sauvanet A, Belghiti J. Risk of major liver resection in patients with underlying chronic liver disease: a reappraisal. *Ann Surg* 1999; **229**: 210-215
- 4 Blumberg N, Heal JM. Effects of transfusion on immune function. Cancer recurrence and infection. *Arch Pathol Lab Med* 1994; **118**: 371-379
- 5 Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts--blood transfusion. *N Engl J Med* 1999; **340**: 438-447
- 6 Crowe JP, Gordon NH, Fry DE, Shuck JM, Hubay CA. Breast cancer survival and perioperative blood transfusion. *Surgery* 1989; **106**: 836-841
- 7 Little AG, Wu HS, Ferguson MK, Ho CH, Bowers VD, Segalin A, Staszek VM. Perioperative blood transfusion adversely affects prognosis of patients with stage I non-small-cell lung cancer. *Am J Surg* 1990; **160**: 630-632; discussion 633
- 8 Takemura M, Osugi H, Higashino M, Takada N, Lee S, Kinoshita H. Effect of substituting allogenic blood transfusion with autologous blood transfusion on outcomes after radical oesophagectomy for cancer. *Ann Thorac Cardiovasc Surg* 2005; **11**: 293-300
- 9 Asahara T, Katayama K, Itamoto T, Yano M, Hino H, Okamoto Y, Nakahara H, Dohi K, Moriwaki K, Yuge O. Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma. *World J Surg* 1999; **23**: 676-680
- 10 Fan ST, Ng IO, Poon RT, Lo CM, Liu CL, Wong J. Hepatectomy for hepatocellular carcinoma: the surgeon's role in long-term survival. *Arch Surg* 1999; **134**: 1124-1130
- 11 Gozzetti G, Mazziotti A, Grazi GL, Jovine E, Gallucci A,

- Gruttadauria S, Frena A, Morganti M, Ercolani G, Masetti M. Liver resection without blood transfusion. *Br J Surg* 1995; **82**: 1105-1110
- 12 Makino Y, Yamanoi A, Kimoto T, El-Assal ON, Kohno H, Nagasue N. The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma. *Am J Gastroenterol* 2000; **95**: 1294-1300
 - 13 Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, Yamaguchi N, Mizuno S, Makuuchi M. Perioperative blood transfusion promotes recurrence of hepatocellular carcinoma after hepatectomy. *Surgery* 1994; **115**: 303-309
 - 14 Hirano T, Yamanaka J, Iimuro Y, Fujimoto J. Long-term safety of autotransfusion during hepatectomy for hepatocellular carcinoma. *Surg Today* 2005; **35**: 1042-1046
 - 15 Rees M, Plant G, Wells J, Bygrave S. One hundred and fifty hepatic resections: evolution of technique towards bloodless surgery. *Br J Surg* 1996; **83**: 1526-1529
 - 16 Kajikawa M, Nonami T, Kurokawa T, Hashimoto S, Harada A, Nakao A, Takagi H. Autologous blood transfusion for hepatectomy in patients with cirrhosis and hepatocellular carcinoma: use of recombinant human erythropoietin. *Surgery* 1994; **115**: 727-734
 - 17 Shinozuka N, Koyama I, Arai T, Numajiri Y, Watanabe T, Nagashima N, Matsumoto T, Ohata M, Anzai H, Omoto R. Autologous blood transfusion in patients with hepatocellular carcinoma undergoing hepatectomy. *Am J Surg* 2000; **179**: 42-45
 - 18 EDMONDSON HA, STEINER PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. *Cancer* 1954; **7**: 462-503
 - 19 Itamoto T, Katayama K, Nakahara H, Tashiro H, Asahara T. Autologous blood storage before hepatectomy for hepatocellular carcinoma with underlying liver disease. *Br J Surg* 2003; **90**: 23-28
 - 20 Pulitanò C, Arru M, Bellio L, Rossini S, Ferla G, Aldrighetti L. A risk score for predicting perioperative blood transfusion in liver surgery. *Br J Surg* 2007; **94**: 860-865
 - 21 Foster RS, Costanza MC, Foster JC, Waner MC, Foster CB. Adverse relationship between blood transfusions and survival after colectomy for colon cancer. *Cancer* 1985; **55**: 1195-1201
 - 22 Motoyama S, Okuyama M, Kitamura M, Saito R, Kamata S, Murata K, Ogawa J. Use of autologous instead of allogeneic blood transfusion during esophagectomy prolongs disease-free survival among patients with recurrent esophageal cancer. *J Surg Oncol* 2004; **87**: 26-31
 - 23 Blumberg N, Heal JM. Effects of transfusion on immune function. Cancer recurrence and infection. *Arch Pathol Lab Med* 1994; **118**: 371-379
 - 24 Kwon AH, Matsui Y, Kamiyama Y. Perioperative blood transfusion in hepatocellular carcinomas: influence of immunologic profile and recurrence free survival. *Cancer* 2001; **91**: 771-778
 - 25 Kitagawa K, Taniguchi H, Mugitani T, Koh T, Obayashi T, Kunishima S, Yamaguchi A, Yamagishi H. Safety and advantage of perioperative autologous blood transfusion in hepatic resection for hepatocellular carcinoma. *Anticancer Res* 2001; **21**: 3663-3667
 - 26 Cohen JA, Brecher ME. Preoperative autologous blood donation: benefit or detriment? A mathematical analysis. *Transfusion* 1995; **35**: 640-644
 - 27 Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. Second of two parts--blood conservation. *N Engl J Med* 1999; **340**: 525-533
 - 28 Kasper SM, Ellering J, Stachwitz P, Lynch J, Grunenberg R, Buzello W. All adverse events in autologous blood donors with cardiac disease are not necessarily caused by blood donation. *Transfusion* 1998; **38**: 669-673
 - 29 Renner SW, Howanitz PJ, Bachner P. Preoperative autologous blood donation in 612 hospitals. A College of American Pathologists' Q-Probes study of quality issues in transfusion practice. *Arch Pathol Lab Med* 1992; **116**: 613-619

S- Editor Tian L L- Editor Cant MR E- Editor Zhang DN

Clinical Science

Mural nodule in branch duct–type intraductal papillary mucinous neoplasms of the pancreas is a marker of malignant transformation and indication for surgery

Hirofumi Akita, M.D., Ph.D., Yutaka Takeda, M.D., Ph.D.*,
Hiromitsu Hoshino, M.D., Hiroshi Wada, M.D., Ph.D., Shogo Kobayashi, M.D., Ph.D.,
Shigeru Marubashi, M.D., Ph.D., Hidetoshi Eguchi, M.D., Ph.D.,
Masahiro Tanemura, M.D., Ph.D., Masaki Mori, M.D., Ph.D.,
Yuichiro Doki, M.D., Ph.D., Hiroaki Nagano, M.D., Ph.D.

Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita-City, Osaka, Japan

KEYWORDS:

IPMN;
Branch duct type;
Mural nodule;
Malignancy;
Predictive factor

Abstract

BACKGROUND: The management of branch duct–type intraductal papillary mucinous neoplasms (IPMNs) remains controversial. This study aimed to elucidate the preoperative clinical factors that identify high-risk malignant transformation in branch duct–type IPMN.

METHODS: We retrospectively evaluated 38 patients diagnosed with branch duct–type IPMN who underwent pancreatectomy, identifying different preoperative factors between adenoma (intraductal papillary mucinous adenoma [IPMA]) and carcinoma (intraductal papillary mucinous carcinoma [IPMC]).

RESULTS: Twelve patients were diagnosed with IPMC. The mean tumor size was 31.9 ± 11.8 mm for IPMA and 35.7 ± 17.1 mm for IPMC ($P = .467$). No significant differences were found between IPMA and IPMC patients with regard to age, sex, symptoms, and tumor number. The mean diameter of the main pancreatic duct was significantly larger in IPMCs (8.3 ± 5.9 mm) compared with IPMAs (4.7 ± 2.3 mm; $P = .011$). The mural nodule was a good predictor of malignancy ($P = .0002$) and was identified as the only independent and significant marker of IPMC in multivariate analysis.

CONCLUSIONS: The presence of mural nodules is a potentially suitable marker for differentiating IPMC from IPMA, and is important for making decisions about surgical interventions.

© 2011 Elsevier Inc. All rights reserved.

Recent advances in diagnostic imaging have resulted in an increased frequency of diagnosis for cystic mucin-producing pancreatic neoplasms.^{1–4} In 2000, the World Health Organization and the Armed Forces Institute of

Pathology classified these tumors into 2 distinct entities: intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms.^{5,6} IPMNs are premalignant lesions originating from a large pancreatic duct that progresses from adenoma (intraductal papillary mucinous adenoma [IPMA]) to carcinoma (intraductal papillary mucinous carcinoma [IPMC]).^{7,8} Many recent clinico-pathologic studies have reported that the rate of malig-

* Corresponding author. Tel.: +81-6-6879-3251; fax: +81-6-6879-3255.

E-mail address: ytakeda@gesurg.med.osaka-u.ac.jp

Manuscript received February 8, 2010; revised manuscript June 9, 2010

nancy for IPMN varies according to the region of the pancreatic duct where the tumor originates. An IPMN arising from the main pancreatic duct (MPD) is more aggressive than those arising from the branch duct. In fact, the reported rate of malignancy for the MPD type ranges from 57% to 92%,^{4,9-12} and surgical resection is recommended for all MPD types. By contrast, the rate of malignancy for the branch duct type is relatively low, reportedly 6% to 46%.^{2,13-15} Thus, differentiating between IPMC and IPMA is clinically relevant and important. In this regard, several tumor features are reported to allow discrimination of IPMC from IPMA, including tumor size, MPD diameter, and the presence of a mural nodule in the cystic lesion.^{8,10,15} However, the significance of these parameters is currently debated and further investigation is necessary.

The purpose of the present study was to elucidate the preoperative clinical features of IPMA and IPMC and use multivariate regression analysis for the differentiation of the 2 lesion types, and consequently the choice of surgery or other alternative therapies.

Patients and Methods

Patients

This study was performed retrospectively. From March 1992 to November 2007, 46 patients who were diagnosed preoperatively with IPMN underwent surgical treatment at Osaka University Hospital. Before surgery, all patients received clinical evaluation and routine laboratory tests including tumor markers and imaging studies (abdominal ultrasonography, computed tomography [CT], and endoscopic retrograde cholangiopancreatography). Magnetic resonance imaging (MRI) and magnetic resonance imaging cholangiopancreatography (MRCP) also were performed in most patients. Pancreatic juice cytology and intraductal ultrasonography were performed when possible.

Definition of IPMN type and surgical indication

The type of IPMN was established by imaging studies and consultation with radiologists, internists, and surgeons. The following definitions were used. The MPD type was diagnosed in the presence of a mural nodule in the main duct only together with pancreatic duct dilatation. The complex type represented a mural nodule in the main duct with dilatation of a branch of the pancreatic duct. The branch pancreatic duct type was diagnosed in the presence of a dilated branch of the pancreatic duct and a lack of a mural nodule in the tumor in the main duct, with or without dilatation of the main duct. A pancreatic duct measuring more than 4 mm was regarded as dilated.

Based on the international consensus guidelines established in 2006,⁸ the treatment strategy for IPMN in our




Figure 1 - Therapeutic strategy for branch duct-type IPMN. Surgical resection was performed for all patients with an MPD diameter greater than 7 mm and patients with an MPD diameter that was not more than 7 mm but who had a tumor size greater than 30 mm or an apparent mural nodule in the tumor. Patients with an MPD smaller than 7 mm, tumor size less than 30 mm, and no apparent mural nodule in the tumor were not indicated for surgery but were followed up by CT or MRI every 3 to 6 months.

institute was as follows. The main pancreatic duct type and complex type were indication for surgery at diagnosis. For the branch type, all patients with an MPD diameter of 7 mm or greater were indicated for resection. An MPD diameter of less than 7 mm, tumor size of 30 mm or greater, or the presence of a mural nodule also was an indication for surgery. Patients with an MPD diameter of less than 7 mm, tumor size of less than 30 mm, and no apparent mural nodule in the tumor were followed up by CT or MRI every 3 to 6 months (Fig. 1). Most patients enrolled in this study underwent surgery in accordance with this algorithm, and 8 patients underwent resection after more than 1 year of follow-up evaluation because the tumors in these patients were not resected at the first diagnosis, so they were followed up. More than 1 year after the first diagnosis, the patients had surgery because of tumor growth of more than 30 mm in 5 patients, the dilatation of MPD of more than 7 mm in 5 patients, and the appearance of a mural nodule in 4 patients. More than 2 factors appeared in the same patient, so the total number is more than 8. Inevitably, the earlier-described criteria varied slightly in some of the patients included in this study because resection was performed before the guidelines became available. All surgeries included confirmation of a negative surgical margin using frozen sections during surgery.

Patient enrollment

Among the 46 patients diagnosed with IPMN, 38 were classified as branch pancreatic duct type and all were enrolled in this study. Table 1 presents the patient characteristics. The sample included 20 men and 18 women with a

Table 1 Characteristics of patients with branch pancreatic duct-type IPMN

Age, y	62.6 ± 8.9
Sex, male/female	20/18
Symptoms, yes/no	18/19
Tumor size, mm	36.0 ± 15
Mural nodule, yes/no	15/23
Dilatation of MPD, yes/no	24/14
Postoperative diagnosis	
IPMA/IPMC (invasive IPMC)/others	20/12 (9)/6
Pathologic MPD invasion, yes/no	7/25
Number of tumors, single/multiple	32/6
Surgery, PD/DP/others	22/9/4
Recurrence, yes/no	5/33

Data are the mean ± SD or the number of patients.

DP = distal pancreatectomy; PD = pancreatoduodenectomy.

mean age ± standard deviation of 62.6 ± 8.9 years. Approximately half of the patients were asymptomatic at the first visit. The mean tumor size was 36.0 ± 15.0 mm, and a mural nodule was observed in 15 patients. Dilatation of the MPD was observed in 24 patients, and the mean diameter was 6.1 ± 4.4 mm. Pancreatoduodenectomy, including subtotal stomach-preserved pancreatoduodenectomy and pylorus-preserved pancreatoduodenectomy, was performed in 22 patients, distal pancreatectomy was performed in 9 patients, and other surgical techniques, including middle pancreatectomy, was performed in 4 patients. The postoperative pathologic findings confirmed the diagnosis of IPMN in 32 patients, including invasive ductal carcinoma derived from IPMN, but 6 patients were diagnosed with other diseases: serous cyst adenoma in 3 patients, mucinous cystic neoplasms in 2 patients, and chronic pancreatitis in 1 patient. Thus, we excluded these 6 patients from further analysis.

Statistical analysis and ethical issues

Data are expressed as mean ± standard deviation. Differences in continuous preoperative factors between IPMA and IPMC patients were analyzed using the Student *t* test.

Table 2 Clinicopathologic characteristics of patients according to the type of pancreatic tumor

	IPMA	IPMC	<i>P</i> value
Total patients	20	12	
Age, y	65.3 ± 8.5	62.6 ± 7.5	.376
Sex, male/female	13/7	6/6	.474
Symptoms, yes/no	7/12	8/4	.149
Tumor size, mm	31.9 ± 11.8	35.7 ± 17.1	.467
Diameter of MPD, mm	4.7 ± 2.3	8.7 ± 5.9	.011
Number of tumors,			
single/multiple	16/4	10/2	.99
Mural nodule, no/yes	17/3	2/10	.0002

Data are the mean ± SD or the number of patients.




Figure 2 The distribution of IPMN patients by tumor size and MPD diameter. The relationship between the diameter of the MPD and tumor size was not significant. IPMA is indicated by a white circle (○) and IPMC is indicated by a black circle (●). In 22 patients with an MPD diameter less than 7 mm, 5 (22.7%) had IPMC, whereas 7 patients (70.0%) among 10 with an MPD diameter greater than 7 mm had IPMC (*P* = .018).

The Fisher exact test was used to compare discrete variables. A *P* value of less than .05 indicated significance.

The study protocol was approved by the Human Ethics Review Committee of Osaka University Hospital, and a signed consent form was obtained from each subject.

Results

In 32 patients with branch-type IPMN, 12 patients were diagnosed with IPMC; 3 patients had noninvasive or microinvasive IPMC and 9 had invasive IPMC, including invasive ductal adenocarcinoma derived from IPMC (Table 1). The mean age of the 20 patients with IPMA was 65.3 ± 8.6 years, whereas the mean age of patients with IPMC was 62.6 ± 7.5 years. There were no significant differences between the 2 groups with regard to age, sex, symptoms, and the number of tumors (Table 2). Although the difference between the mean tumor size in IPMA and IPMC patients was not significant (31.9 ± 11.8 mm vs 35.7 ± 17.1 mm, respectively; *P* = .467), the mean diameter of the MPD in IPMA patients was significantly smaller than that of IPMC patients (4.7 ± 2.3 mm vs 8.3 ± 5.9 mm, respec-

Table 3 Differences between benign and malignant pancreatic tumors according to the diameter of the MPD

	MPD, mm	
	<7	≥7
IPMA	17	3
IPMC	5	7

P = .018




Figure 3 The distribution of IPMN patients with an MPD diameter less than 7 mm. (A) patients lacking a mural nodule; (B) patients with a mural nodule. All 14 patients lacking a mural nodule had IPMA, regardless of tumor size, whereas among the 8 patients with mural nodules, 5 (63%) had IPMC ($P = .0021$).

tively; $P = .011$). A mural nodule was observed in preoperative imaging in 13 patients, 10 of whom (76.9%) had IPMC, whereas only 2 patients (10.5%) among 19 patients without mural nodules had IPMC, and the relationship between the presence of a mural nodule and IPMC was significant ($P = .0002$; Table 2). The relationship between the MPD diameter and tumor size was not significant (Fig. 2).

When the patients were divided into 2 groups based on the diameter of the MPD, 22 patients had a diameter less than 7 mm. Among these patients, 5 patients (22.7%) had IPMC. Ten patients had an MPD diameter of 7 mm or greater, 7 of whom (70.0%) had IPMC. The difference in IPMC occurrence between the 2 groups was significant ($P = .018$; Table 3).

The tumor size did not allow us to distinguish between IPMA and IPMC (data not shown). Among the 22 patients with an MPD diameter less than 7 mm, mural nodules were not observed in 14 patients and all had IPMA. By contrast, 5 patients (63%) among the remaining 8 patients with apparent mural nodules had IPMC ($P = .0021$; Fig. 3). Multivariate analysis identified the presence of a mural nodule as the only independent and significant factor that allows differentiation between IPMC and IPMA, whereas the MPD diameter was a marginal predictive factor ($P = .063$; Table 4).

In 8 patients who underwent surgery after more than 1 year of follow-up evaluation, 6 (75%) patients had IPMC. Five (83%) of these cases were noninvasive or showed microinvasion. In the remaining 24 patients who underwent surgery without a follow-up period, 6 (25%) patients had

IPMC, only 2 (33%) of which were noninvasive or showed microinvasion ($P = .014$).

Comments

IPMNs are a well-recognized type of pancreatic tumor and represent roughly 1% of pancreatic exocrine tumors and 12% of cystic pancreatic tumors.¹⁶ Despite being larger than ductal adenocarcinomas, IPMNs appear to be biologically less aggressive than ductal adenocarcinomas, with a lower incidence of nodal positivity, perineural invasion, and vascular invasion, and a significantly better 5-year survival rate (62% vs 19%). Levy et al¹⁷ reported that the actual risk of developing high-grade dysplasia or invasive carcinoma from IPMA at 2 years and 5 years for the branch duct type was 9% and 15%, respectively, whereas the risks for the main duct type, including combined type, were 58% and 63%, respectively. These data suggest that one can take a wait-and-see approach in most patients with branch duct-type IPMN.¹⁸ By contrast, IPMC has been reported to acquire aggressive behavior similar to that of general invasive ductal adenocarcinoma of the pancreas once it invades the pancreatic parenchyma.¹⁹ Therefore, discriminating between IPMC and IPMA is important, especially in the case of the branch duct type with low incidence of malignancy.

Table 4 Results of univariate and multivariate analyses

	IPMA	IPMC	Univariate analysis, P value	Multivariate analysis expected P value (odds ratio, range)
Tumor size, <30/≥30 mm	8/12	3/9	.4647	.813 (1.24, .21–7.32)
MPD diameter, <7/≥7 mm	17/3	5/7	.0184	.063 (5.67, .91–35.2)
Symptoms, yes/no	12/7	4/8	.1489	.512 (1.79, .10–3.19)
Mural nodule, no/yes	17/3	2/10	.0002	.019 (25.0, 3.29–200)

The management of branch pancreatic duct-type IPMN continues to be a topic of considerable controversy, although an increasing number of reports have provided information about its clinicopathologic characteristics. Tumor size, MPD diameter, and the presence of a mural nodule in the tumor are reported to be important in predicting malignancy.^{8,15,20} Some studies have reported that a tumor size of more than 30 mm is associated with an increased risk of malignant change,^{10,15,20} and recently Jang et al²¹ reported that 20 mm is a useful cut-off value for tumor size when evaluating malignancy. Although an increase in tumor size undoubtedly is associated with increased malignant risk, we sometimes experience cases with no signs of malignancy despite a gradual increase in the size of the cystic lesions.

The frequencies of mural nodules and MPD dilatation are likely to increase with increased tumor size; thus, we need to examine the true importance of these factors in regards to the risk of malignancy in IPMNs. In addition, with recent advances in imaging modalities, small nodules can be detected, and the identification of mural nodules may allow for the discrimination of IPMC from IPMA.^{22,23} In the present retrospective study, the selection of various cut-off values for tumor size did not allow for the diagnosis of IPMC. This result may have occurred in part because, in our hospital, the criteria for resection was applicable to almost all enrolled patients. Therefore, our study included many cases with tumors measuring more than 30 mm in diameter. In other words, the present study showed that tumors without dilatation of the MPD or the presence of mural nodules are associated with a low risk of malignancy, even when the tumor size is more than 30 mm. Multivariate analysis identified the presence of a mural nodule as the only significant factor related to the risk of malignancy and the most useful in predicting malignant changes. Among 8 patients with more than 1 year of follow-up evaluation, 6 (75%) patients had IPMC, 5 of whom (83%) had noninvasive tumors or tumors that showed microinvasion, whereas 6 (25%) of the remaining 24 patients without any follow-up evaluation had IPMC, only 2 of which (33%) were noninvasive or showed microinvasion. These findings indicate that, in patients followed up before surgery, IPMC was diagnosed selectively and at early stages, so the algorithm for IPMN treatment in this study is adequate. Furthermore, among these 8 patients, the 4 patients with a mural nodule had IPMC, whereas 4 of the 5 patients with MPD dilatation and 3 of the 5 patients with tumor growth had IPMC. This result also indicated that the presence of a mural nodule is useful for follow-up evaluation.

The procedure used to detect the mural nodule also may be important. In our institute, the presence of a mural nodule is diagnosed mainly by CT (high-resolution CT) or MRI (MRCP) because CT and MRI (MRCP) can provide clearer images than US or endoscopic retrograde cholangiopancreatography. Liu et al²³ also reported that

CT is recommended to evaluate IPMN. Jang et al²¹ reported the presence of mural nodules in many patients with benign IPMN, and the malignant ratio for patients with mural nodules in our study was much different from the ratio in the study by Jang et al²¹ (76.9% vs 33.3%, respectively). However, the rate of malignancy in the report by Jang et al²¹ seemed low. For example, Rodriguez et al²⁰ had 19 patients (82.6%) who were diagnosed with malignancy among 23 patients with mural nodules, and Sugiyama et al¹⁰ had 8 patients (80.0%) who were diagnosed with malignancy among 10 patients with mural nodules. We do not know why this discrepancy occurred. The presence of a mural nodule was diagnosed by CT or MRI in our institute, but the method of mural nodule detection by Jang et al²¹ was not stated clearly, so the diagnostic criteria may have been different from ours.

IPMN will be of increasing significance as a premalignant lesion originating from a large pancreatic duct. Additional studies are needed to elucidate the risk of malignancy in IPMN, especially in the branch type regarded as a relatively low-risk group, and we believe that a mural nodule could play an important role in predicting cancerous changes and deciding treatment strategy.

References

1. D'Angelica M, Brennan MF, Suriawinata AA, et al. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. *Ann Surg* 2004;239:400-8.
2. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. *Ann Surg* 2004;239:788-97; discussion 797-9.
3. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. *Ann Surg* 2001;234:313-21; discussion 321-2.
4. Salvia R, Fernandez-del Castillo C, Bassi C, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. *Ann Surg* 2004;239:678-85; discussion 685-7.
5. Longnecker DS, Adler G, Hruban RH, et al. *Intraductal Papillary Mucinous Neoplasms of the Pancreas*. Lyon: IARC Press; 2000.
6. Solcia E, Capella C, Kloppel G. *Atlas of Tumor Pathology*. Washington, DC: Armed Forces Institute of Pathology; 1997.
7. Longnecker DS, Adsay NV, Fernandez-del Castillo C, et al. Histopathological diagnosis of pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms: interobserver agreement. *Pancreas* 2005;31:344-9.
8. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. *Pancreatology* 2006;6:17-32.
9. Doi R, Fujimoto K, Wada M, et al. Surgical management of intraductal papillary mucinous tumor of the pancreas. *Surgery* 2002;132:80-5.
10. Sugiyama M, Izumisato Y, Abe N, et al. Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. *Br J Surg* 2003;90:1244-9.
11. Terris B, Ponsot P, Paye F, et al. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. *Am J Surg Pathol* 2000;24:1372-7.